Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 7, 2006, Pages 1990-1994

  Asche, Christian ^a   Dumy, Pascal ^a   Carrez, Danièle ^b   Croisy, Alain ^b   Demeunynck, Martine ^a  

^a Centre National de la Recherche Scientifique   (France)

^b INSERM   (France)

Author keywords

Acridine; GDEPT; Nitroreductase; Prodrug

Indexed keywords

3 AMINO 4 HYDROXYMETHYLACRIDINE; 4 NITROBENZYLCARBAMATE; ACRIDINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYTOSTATIC AGENT; NITROREDUCTASE; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; COLON CARCINOMA; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME SUBSTRATE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; SOLVOLYSIS;

ACRIDINES; ANIMALS; CARBAMATES; CRICETINAE; CRICETULUS; GENE THERAPY; HT29 CELLS; HUMANS; NITROREDUCTASES; PRODRUGS;

ESCHERICHIA COLI;

EID: 33144455024     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.089     Document Type: Article

References (28)

1. T.A. Connors, and R.J. Knox Stem Cells 13 1995 501
2. W.A. Denny Eur. J. Med. Chem. 36 2001 577
3. G. Xu, and H.L. McLeod Clin. Cancer Res. 7 2001 3314
4. M. Rooseboom, J.N.M. Commandeur, and N.P.E. Vermeulen Pharmacol. Rev. 56 2004 53
5. I. Niculescu-Duvaz, and C.J. Springer Adv. Drug Deliv. Rev. 26 1997 151
6. I.A. McNeish, P.F. Searle, L.S. Young, and D.J. Kerr Adv. Drug Deliv. Rev. 26 1997 173
7. W.A. Denny Curr. Pharm. Des. 8 2002 1349
8. W.A. Denny J. Biomed. Biotechnol. 1 2003 48
9. N.P. Michael, J.K. Brehm, G.M. Anlezark, and N.P. Minton Fems. Microbiol. Lett. 124 1994 195
10. R.J. Knox, F. Friedlos, R.F. Sherwood, R.G. Melton, and G.M. Anlezark Biochem. Pharmacol. 44 1992 2297
11. G.M. Anlezark, R.G. Melton, R.E. Sherwood, B. Coles, F. Friedlos, and R.J. Knox Biochem. Pharmacol. 44 1992 2289
12. R.J. Knox, F. Friedlos, and M. Boland Cancer Metast. Rev. 12 1993 195
13. G.N. Parkinson, J.V. Skelly, and S. Neidle J. Med. Chem. 43 2000 3624
14. A.L. Lovering, E.I. Hyde, P.F. Searle, and S.A. White J. Mol. Biol. 309 2001 203
15. A.B. Mauger, P.J. Burke, H.H. Somani, F. Friedlos, and R.J. Knox J. Med. Chem. 37 1994 3452
16. M.J. Sagnou, P.W. Howard, S.J. Gregson, E. Eno-Amooquaye, P.J. Burke, and D.E. Thurston Bioorg. Med. Chem. Lett. 10 2000 2083
17. M.P. Hay, W.R. Wilson, and W.A. Denny Bioorg. Med. Chem. Lett. 9 1999 3417
18. F.M.H. de Groot, W.J. Loos, R. Koekkoek, L.W.A. van Berkom, G.F. Busscher, A.E. Seelen, C. Albrecht, P. de Bruijn, and H.W. Scheeren J. Org. Chem. 66 2001 8815
19. F. Charmantray, M. Demeunynck, D. Carrez, A. Croisy, A. Lansiaux, C. Bailly, and P. Colson J. Med. Chem. 46 2003 967
20. F. Charmantray, A. Duflos, J. Lhomme, and M. Demeunynck J. Chem. Soc., Perkin Trans. 1 2001 2962
21. F. Charmantray, M. Demeunynck, J. Lhomme, and A. Duflos J. Org. Chem. 66 2001 8222
22. 5: C, 65.50; H, 4.25; N, 10.42. Found: C, 65.61; H, 4.30; N, 10.30).
23. 9: C, 61.86; H, 3.81; N, 9.62. Found: C, 61.59; H, 3.92; N, 9.58).
24. 5: C, 65.21; H, 5.47; N, 7.60. Found: C, 65.34; H, 5.41; N, 7.52).
25. 3: C, 69.66; H, 5.85; N, 9.03. Found: C, 69.74; H, 6.02; N, 8.90).
26. -5 M, 5 equiv); 1410 μl of buffer. This was done in order to test the stability of the compounds under these conditions. Reactions were followed by HPLC as a function of time by removing aliquots (250 μl) and injecting them onto the HPLC column. Peak areas of UV chromatograms were used to determine both the disappearance of the starting compounds as well as the appearance of the reaction products.
27. 50 values were extracted from regression curves obtained with experimental points.
28. T. Mosmann J. Immunol. Methods 65 1983 55